Global DNA and RNA Methylation Signature in Response to Antipsychotic Treatment in First-Episode Schizophrenia Patients

Background: Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropsychiatric disease and treatment 2024-07, Vol.20, p.1435
Hauptverfasser: Angelin, Mary, Gopinath, Padmavathi, Raghavan, Vijaya, Thara, Rangaswamy, Ahmad, Faraz, Munirajan, Arasamabattu Kannan, Sudesh, Ravi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 1435
container_title Neuropsychiatric disease and treatment
container_volume 20
creator Angelin, Mary
Gopinath, Padmavathi
Raghavan, Vijaya
Thara, Rangaswamy
Ahmad, Faraz
Munirajan, Arasamabattu Kannan
Sudesh, Ravi
description Background: Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls. Results: The methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers. Conclusion: The study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients. Keywords: schizophrenia, global methylation, treatment response, 5mC, 5hmC, m6A
doi_str_mv 10.2l47/NDT.S466502
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A809283672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A809283672</galeid><sourcerecordid>A809283672</sourcerecordid><originalsourceid>FETCH-LOGICAL-g672-95b98bd2bff9ae88c282a0ff1d84cd6c2543062affc741bcf6421dfd1f1f78593</originalsourceid><addsrcrecordid>eNptjTtPwzAAhD2ARClM_AFLzCm2kzjOGPUFUimoyV45fiRGqR3FRqj8eoxgYEA3nHT67g6AO4wWZMiKh_2qWdQZpTkiF2CGcUETmhJ2Ba69f0MoLUrGZuBjO7iWD3C1ryC3Eh6iP6vQnwcejLOwNp3l4X1S0Fh4UH501isYHKxsMKM_i94FI2AzKR5OyoZvbGMmH5L1aLyTCtaiN59u7CdlDYevcTZi_gZcaj54dfvrc9Bs1s3yMdm9bJ-W1S7paEGSMm9L1krSal1yxZggjHCkNZYsE5IKkmcpooRrLYoMt0LTjGCpJdZYFywv0zm4_5nt-KCOxmoXJi5OxotjxVBJWBpvIrX4h4qS6mSEs0qbmP8pfAHRBGzO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Global DNA and RNA Methylation Signature in Response to Antipsychotic Treatment in First-Episode Schizophrenia Patients</title><source>Taylor &amp; Francis Open Access</source><source>PubMed Central Free</source><source>DOAJ Directory of Open Access Journals</source><source>Dove Press Free</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Angelin, Mary ; Gopinath, Padmavathi ; Raghavan, Vijaya ; Thara, Rangaswamy ; Ahmad, Faraz ; Munirajan, Arasamabattu Kannan ; Sudesh, Ravi</creator><creatorcontrib>Angelin, Mary ; Gopinath, Padmavathi ; Raghavan, Vijaya ; Thara, Rangaswamy ; Ahmad, Faraz ; Munirajan, Arasamabattu Kannan ; Sudesh, Ravi</creatorcontrib><description>Background: Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls. Results: The methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers. Conclusion: The study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients. Keywords: schizophrenia, global methylation, treatment response, 5mC, 5hmC, m6A</description><identifier>ISSN: 1176-6328</identifier><identifier>DOI: 10.2l47/NDT.S466502</identifier><language>eng</language><publisher>Dove Medical Press Limited</publisher><subject>Antipsychotic drugs ; Care and treatment ; DNA ; Dosage and administration ; Genetic aspects ; Health aspects ; Methylation ; Psychological aspects ; RNA ; Schizophrenia</subject><ispartof>Neuropsychiatric disease and treatment, 2024-07, Vol.20, p.1435</ispartof><rights>COPYRIGHT 2024 Dove Medical Press Limited</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Angelin, Mary</creatorcontrib><creatorcontrib>Gopinath, Padmavathi</creatorcontrib><creatorcontrib>Raghavan, Vijaya</creatorcontrib><creatorcontrib>Thara, Rangaswamy</creatorcontrib><creatorcontrib>Ahmad, Faraz</creatorcontrib><creatorcontrib>Munirajan, Arasamabattu Kannan</creatorcontrib><creatorcontrib>Sudesh, Ravi</creatorcontrib><title>Global DNA and RNA Methylation Signature in Response to Antipsychotic Treatment in First-Episode Schizophrenia Patients</title><title>Neuropsychiatric disease and treatment</title><description>Background: Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls. Results: The methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers. Conclusion: The study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients. Keywords: schizophrenia, global methylation, treatment response, 5mC, 5hmC, m6A</description><subject>Antipsychotic drugs</subject><subject>Care and treatment</subject><subject>DNA</subject><subject>Dosage and administration</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Methylation</subject><subject>Psychological aspects</subject><subject>RNA</subject><subject>Schizophrenia</subject><issn>1176-6328</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptjTtPwzAAhD2ARClM_AFLzCm2kzjOGPUFUimoyV45fiRGqR3FRqj8eoxgYEA3nHT67g6AO4wWZMiKh_2qWdQZpTkiF2CGcUETmhJ2Ba69f0MoLUrGZuBjO7iWD3C1ryC3Eh6iP6vQnwcejLOwNp3l4X1S0Fh4UH501isYHKxsMKM_i94FI2AzKR5OyoZvbGMmH5L1aLyTCtaiN59u7CdlDYevcTZi_gZcaj54dfvrc9Bs1s3yMdm9bJ-W1S7paEGSMm9L1krSal1yxZggjHCkNZYsE5IKkmcpooRrLYoMt0LTjGCpJdZYFywv0zm4_5nt-KCOxmoXJi5OxotjxVBJWBpvIrX4h4qS6mSEs0qbmP8pfAHRBGzO</recordid><startdate>20240730</startdate><enddate>20240730</enddate><creator>Angelin, Mary</creator><creator>Gopinath, Padmavathi</creator><creator>Raghavan, Vijaya</creator><creator>Thara, Rangaswamy</creator><creator>Ahmad, Faraz</creator><creator>Munirajan, Arasamabattu Kannan</creator><creator>Sudesh, Ravi</creator><general>Dove Medical Press Limited</general><scope/></search><sort><creationdate>20240730</creationdate><title>Global DNA and RNA Methylation Signature in Response to Antipsychotic Treatment in First-Episode Schizophrenia Patients</title><author>Angelin, Mary ; Gopinath, Padmavathi ; Raghavan, Vijaya ; Thara, Rangaswamy ; Ahmad, Faraz ; Munirajan, Arasamabattu Kannan ; Sudesh, Ravi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g672-95b98bd2bff9ae88c282a0ff1d84cd6c2543062affc741bcf6421dfd1f1f78593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antipsychotic drugs</topic><topic>Care and treatment</topic><topic>DNA</topic><topic>Dosage and administration</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Methylation</topic><topic>Psychological aspects</topic><topic>RNA</topic><topic>Schizophrenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Angelin, Mary</creatorcontrib><creatorcontrib>Gopinath, Padmavathi</creatorcontrib><creatorcontrib>Raghavan, Vijaya</creatorcontrib><creatorcontrib>Thara, Rangaswamy</creatorcontrib><creatorcontrib>Ahmad, Faraz</creatorcontrib><creatorcontrib>Munirajan, Arasamabattu Kannan</creatorcontrib><creatorcontrib>Sudesh, Ravi</creatorcontrib><jtitle>Neuropsychiatric disease and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Angelin, Mary</au><au>Gopinath, Padmavathi</au><au>Raghavan, Vijaya</au><au>Thara, Rangaswamy</au><au>Ahmad, Faraz</au><au>Munirajan, Arasamabattu Kannan</au><au>Sudesh, Ravi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Global DNA and RNA Methylation Signature in Response to Antipsychotic Treatment in First-Episode Schizophrenia Patients</atitle><jtitle>Neuropsychiatric disease and treatment</jtitle><date>2024-07-30</date><risdate>2024</risdate><volume>20</volume><spage>1435</spage><pages>1435-</pages><issn>1176-6328</issn><abstract>Background: Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls. Results: The methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers. Conclusion: The study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients. Keywords: schizophrenia, global methylation, treatment response, 5mC, 5hmC, m6A</abstract><pub>Dove Medical Press Limited</pub><doi>10.2l47/NDT.S466502</doi></addata></record>
fulltext fulltext
identifier ISSN: 1176-6328
ispartof Neuropsychiatric disease and treatment, 2024-07, Vol.20, p.1435
issn 1176-6328
language eng
recordid cdi_gale_infotracmisc_A809283672
source Taylor & Francis Open Access; PubMed Central Free; DOAJ Directory of Open Access Journals; Dove Press Free; EZB-FREE-00999 freely available EZB journals
subjects Antipsychotic drugs
Care and treatment
DNA
Dosage and administration
Genetic aspects
Health aspects
Methylation
Psychological aspects
RNA
Schizophrenia
title Global DNA and RNA Methylation Signature in Response to Antipsychotic Treatment in First-Episode Schizophrenia Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T02%3A00%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Global%20DNA%20and%20RNA%20Methylation%20Signature%20in%20Response%20to%20Antipsychotic%20Treatment%20in%20First-Episode%20Schizophrenia%20Patients&rft.jtitle=Neuropsychiatric%20disease%20and%20treatment&rft.au=Angelin,%20Mary&rft.date=2024-07-30&rft.volume=20&rft.spage=1435&rft.pages=1435-&rft.issn=1176-6328&rft_id=info:doi/10.2l47/NDT.S466502&rft_dat=%3Cgale%3EA809283672%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A809283672&rfr_iscdi=true